Nanotechnology and vaccine development

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 5, 2014, Pages 227-235

  Kim, Mi Gyeong ^a   Park, Joo Yeon ^a   Shon, Yuna ^a   Kim, Gunwoo ^a   Shim, Gayong ^a   Oh, Yu Kyoung ^a  

^a Seoul National University   (South Korea)

Author keywords

Carbon nanomaterials; Emulsions; Liposomes; Nanotechnology; Polymeric nanocarriers; Vaccine delivery

Indexed keywords

BIOPOLYMER; CARBON NANOPARTICLE; CARBON NANOTUBE; CHITOSAN; HEMAGGLUTININ; LIPOSOME; MIFAMURTIDE; POLYLACTIC ACID; POLYSORBATE 80; SINGLE WALLED NANOTUBE; SORBITAN TRIOLEATE; VACCINE; WATER OIL CREAM;

CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; EMULSION; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LIPID BILAYER; LIPOSOMAL DELIVERY; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 84910055747     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.06.002     Document Type: Review

References (72)

1. Naiman B.M., Alt D., Bolin C.A., et al. Protective killed leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and γδ T lymphocytes. Infect Immun 2001, 69:7550-7558.
2. Epstein J.E., Tewari K., Lyke K.E., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011, 334:475-480.
3. Saha A., Chowdhury M.I., Nazim M., et al. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. Vaccine 2013, 31:647-652.
4. Norton E.B., Lawson L.B., Mahdi Z., et al. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 2012, 80:2426-2435.
5. Luke J.M., Simon G.G., Söderholm J., et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011, 85:1370-1383.
6. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
7. Dunkle A., Blanchette C., Boone T., et al. Co-delivery of adjuvant and subunit antigens via a nanoparticle platform induces tissue-associated and systemic adaptive immune responses (P4409). J Immunol 2013, 190:205-214.
8. Demento S.L., Cui W., Criscione J.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33:4957-4964.
9. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013, 3:1-13.
10. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
11. Borges O., Borchard G., Verhoef J.C., et al. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 2005, 299:155-166.
12. Apostolopoulos V., Thalhammer T., Tzakos A.G., et al. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013, ePub.
13. Lepenies B., Lee J., Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 2013, 65:1271-1281.
14. Raghuwanshi D., Mishra V., Suresh M.R., et al. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012, 30:7292-7299.
15. Misumi S., Masuyama M., Takamune N., et al. Targeted delivery of immunogen to primate M cells with tetragalloyl lysine dendrimer. J Immunol 2009, 182:6061-6070.
16. Allison A.G., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
17. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30:2256-2272.
18. Henriksen-Lacey M., Devitt A., Perrie Y. The vesicle size of DDA: TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 2011, 154:131-137.
19. Milicic A., Kaur R., Reyes-Sandoval A., et al. Small cationic DDA: TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS One 2012, 7:e34255.
20. Christensen D., Henriksen-Lacey M., Kamath A.T., et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different invivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release 2012, 160:468-476.
21. Hamborg M., Jorgensen L., Bojsen A.R., et al. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics. Pharm Res 2013, 30:140-155.
22. Kaur R., Bramwell V.W., Kirby D.J., et al. Pegylation of DDA: TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release 2012, 158:72-77.
23. McNeil S.E., Rosenkrands I., Agger E.M., et al. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. J Pharm Sci 2011, 100:1856-1865.
24. Nordly P., Agger E.M., Andersen P., et al. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses invivo. Pharm Res 2011, 28:553-562.
25. Rosenkrands I., Vingsbo-Lundberg C., Bundgaard T.J., et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011, 29:6283-6291.
26. Moon J.J., Suh H., Bershteyn A., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
27. Mašek J., Bartheldyova E., Turanek-Knotigova P., et al. Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant His-tagged antigens: preparation, structural study and immune response towards rHsp90. JControl Release 2011, 151:193-201.
28. Watson D.S., Platt V.M., Cao L., et al. Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clin Vaccine Immunol 2011, 18:289-297.
29. de Veer M., Neeland M., Burke M., et al. Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly(I: C) containing liposomes, in aqueous or oil-based formulations. Vaccine 2013, 31:1012-1018.
30. Lay M., Callejo B., Chang S., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27:3811-3820.
31. Carroll T.D., Matzinger S.R., Barry P.A., et al. Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant. JInfect Dis 2014, 209:24-33.
32. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6:699-710.
33. Vesikari T., Knuf M., Wutzler P., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
34. Calabro S., Tritto E., Pezzotti A., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31:3363-3369.
35. Singh M., Kazzaz J., Ugozzoli M., et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Hum Vaccin Immunother 2012, 8:486-490.
36. Brito L.A., Chan M., Baudner B., et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 2011, 29:6262-6268.
37. Klucker M.F., Dalencon F., Probeck P., et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J Pharm Sci 2012, 101:4490-4500.
38. Cotte J.F., Sonnery S., Martial F., et al. Characterization of surfactants in an oil-in-water emulsion-based vaccine adjuvant using MS and HPLC-MS: structural analysis and quantification. Int J Pharm 2012, 436:233-239.
39. Makidon P.E., Nigavekar S.S., Bielinska A.U., et al. Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulm Drug Deliv 2010, 23:77-89.
40. 805EC induces dendritic cell engulfment of antigen-primed epithelial cells. Vaccine 2013, 31:1072-1079.
41. Lousada-Dietrich S., Jogdand P.S., Jepsen S., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29:3284-3292.
42. Lumsden J.M., Nurmukhambetova S., Klein J.H., et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 2012, 30:3311-3319.
43. Schneider L.P., Schoonderwoerd A.J., Moutaftsi M., et al. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012, 30:4216-4224.
44. Treanor J.J., Essink B., Hull S., et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 2013, 31:5760-5765.
45. Thomas C., Rawat A., Hope-Weeks L., et al. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharm 2011, 8:405-415.
46. Bershteyn A., Hanson M.C., Crespo M.P., et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release 2012, 157:354-365.
47. Moon J.J., Suh H., Polhemus M.E., et al. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 2012, 7:e31472.
48. Gupta P.N., Vyas S.P. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf B Biointerfaces 2011, 82:118-125.
49. Ulery B.D., Kumar D., Ramer-Tait A.E., et al. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 2011, 6:e17642.
50. Torres M.P., Wilson-Welder J.H., Lopac S.K., et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater 2011, 7:2857-2864.
51. Saini V., Jain V., Sudheesh M.S., et al. Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres. J Drug Target 2010, 18:212-222.
52. JF1 Mann, McKay P.F., Arokiasamy S., et al. Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J Control Release 2013, 170:452-459.
53. Y1 Qiao, Huang Y., Qiu C., et al. The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. Biomaterials 2010, 31:115-123.
54. Slutter B., Bal S., Keijzer C., et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010, 28:6282-6291.
55. Sawaengsak C., Mori Y., Yamanishi K., et al. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS PharmSciTech 2014, 15:317-325.
56. Lugade A.A., Bharali D.J., Pradhan V., et al. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine 2013, 9:923-934.
57. Nochi T., Yuki Y., Takahashi H., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010, 9:572-578.
58. Scheinberg D.A., McDevitt M.R., Dao T., et al. Carbon nanotubes as vaccine scaffolds. Adv Drug Deliv Rev 2013, 65:2016-2022.
59. Zeinali M., Jammalan M., Ardestani S.K., et al. Immunological and cytotoxicological characterization of tuberculin purified protein derivative (PPD) conjugated to single-walled carbon nanotubes. Immunol Lett 2009, 126:48-53.
60. Parra J., Abad-Somovilla A., Mercader J.V., et al. Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens. J Control Release 2013, 170:242-251.
61. Schreiber H.A., Prechl J., Jiang H., et al. Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells. J Immunol Methods 2010, 356:47-59.
62. Tkach A.V., Yanamala N., Stanley S., et al. Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small 2013, 9:1686-1690.
63. Wang T., Zou M., Jiang H., et al. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci 2011, 44:653-659.
64. Hafner A.M., Corthésy B., Merkle H.P. Particulate formulations for the delivery of poly(I: C) as vaccine adjuvant. Adv Drug Deliv Rev 2013, 65:1386-1399.
65. Sarti F., Perera G., Hintzen F., et al. Invivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 2011, 32:4052-4057.
66. Luo Z., Li P., Deng J., et al. Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy. J Control Release 2013, 170:259-267.
67. Wilson J.T., Keller S., Manganiello M.J., et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 2013, 7:3912-3925.
68. Primard C., Poecheim J., Heuking S., et al. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. Mol Pharm 2013, 10:2996-3004.
69. Pawar D., Mangal S., Goswami R., et al. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm 2013, 85:550-559.
70. Marre S., Jensen K.F. Synthesis of micro and nanostructures in microfluidic systems. Chem Soc Rev 2010, 39:1183-1202.
71. Sebastian V., Arruebo M., Santamaria J. Reaction engineering strategies for the production of inorganic nanomaterials. Small 2013, ePub.
72. Gomez L., Sebastian V., Irusta S., et al. Scaled-up production of plasmonic nanoparticles using microfluidics: from metal precursors to functionalized and sterilized nanoparticles. Lab Chip 2014, 14:325-332.